MicroMatrices are pleased to announce the publication 5 February 2019  of  a paper  entitled “A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine” in  Scientific Reports. This landmark paper describes the application of our proprietary SpheroMatrices microTMA technology in  a heterotypic human glioblastoma model containing normal neuronal cells…

SpheroMatrices is our proprietary technology for creating a tissue microarray from spheroid microtissues, capturing an entire 96 well experiment on a single microscope slide. The microtissues, aligned in two dimensions, can be serially sectioned for  immunostaining and image analysis. Please watch the SpheroMatrices video to learn more: This versatile technology can be applied for:  Model…

    We are pleased to announce the arrival of our new satellite website: www.spheromatrices.com showcasing our spheroid tissue microarray technology for multiplexed 3D cell culture analytics; don’t miss the video!  

Eurotox-SOT debate, San Antonio 2018 Adverse outcome pathways (AOPs) offer potential  for more streamlined and informative risk assessments of new chemical entities. However defining the thousands of permutations of these complex pathways, encompassing  a broad spectrum of molecular targets, is laborious. As discussed in the Eurotox-SOT debate, held at SOT 2018 in San Antonio, the…

MicroMatrices are pleased to announce the  publication  of  a landmark paper  entitled “Dose-dependent effects on rat liver miRNAs 200a/b and 429: potential early biomarkers of liver carcinogenesis”. The paper, published this week in Toxicology Reports,  https://www.sciencedirect.com/science/article/pii/S2214750018300842, describes the identification of early  microRNA biomarkers for receptor mediated rodent hepatocarcingenesis, illustrating the principle that retrospective analyses can…

SpheroMatrices® spheroid tissue microarray (TMA)  platform preserves  the experimental  layout of your 96 well plate making it possible to compare treatment groups within the same experiment . As the TMA sections are fixed, it is possible to perform Heat-induced Epitope Retrieval (HIER) on  the samples without impacting upon the integrity of the tissue. HIER makes…

MicroMatrices supports compound selection in the following ways: SpheroMatrices, a proprietary spheroid tissue microarray technology for de-risking drug safety/efficacy studies. Addressing translatability issues in preclinical drug testing via new analytical processes for profiling 3D organotypic models: spheroids, organoids, PDX 3D models.  Specialist Investigative Toxicology services for risk assessment. Elucidating toxicological/therapeutic mechanisms through the application of…

Our webinar entitled “Unlocking the Potential of FFPE Tissues for Investigating Mode of Action of Adverse Outcomes & Improving Predictive Ability” was held Thursday 21 September 2017. We were  joined by scientists from  pharmaceutical and agrochemical companies from the US, Europe, and Japan; we were also pleased to have  EPA registrants attending.   We hope attendees found…

MicroMatrices will be attending two meetings this Autumn. OCTOBER: We will be presenting a poster demonstrating analyses we have made of  3D co-culture neuronal/glioblastoma spheroids at the ELRIG Drug Discovery Meeting  in Liverpool 3-4 October: http://elrig.org/portfolio/drug-discovery-2017-elrigdd17/   NOVEMBER: We are attending BIO-Europe in Berlin 6-8 November . If you will also be attending this meeting…

PLEASE JOIN US FOR A WEBINAR : UNLOCKING THE POTENTIAL OF FFPE TISSUES FOR INVESTIGATING  MODE OF ACTION OF ADVERSE OUTCOMES & IMPROVING PREDICTIVE CAPABILITY THURSDAY 21 SEPTEMBER: 3PM BST | 4 PM CEST | 10 AM EDT | 7 AM PDT If an adverse outcome, e g  carcinogenicity,  is observed within regulatory safety assessment studies in rodents, the demonstration of…